Deso

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Deso

Quick Facts

Property Description
Active Ingredients Desogestrel (Progestin), Ethinyl Estradiol (Estrogen)
Form Oral Tablet (Combination product)
Pharmacological Class Combined Hormonal Contraceptive (CHC)
Common Use Prevention of pregnancy (Birth control)
Origin Synthetic steroid compounds

Deso: Combined Hormonal Contraceptive (CHC) Identity

Deso is a prescription-only medication known generically by its active ingredients, Desogestrel and Ethinyl Estradiol. It is classified as a Combined Hormonal Contraceptive (CHC), which belongs to the larger class of Sex Hormone Combinations used for systemic regulation. This designation is clinically recognized for its intended role in providing a highly reliable method of birth control. The drug is administered orally, representing a common and well-studied form of contraception.

Composition and Form: Synthetic Steroid Compounds

The preparation is provided as an oral tablet and is characterized as a combination product containing two synthetic steroid compounds. Desogestrel is classified as a third-generation progestin, a synthetic substance. Ethinyl Estradiol serves as the synthetic estrogen component. This combination of a third-generation progestin with an estrogen differentiates it from older combined oral contraceptives and is characterized by pharmacological data demonstrating its hormonal efficacy.

General Purpose of the Desogestrel/Ethinyl Estradiol Combination

The fundamental purpose of using this combination drug is to ensure contraception through the combined hormonal modulation of the female reproductive system. This is a common use scenario for women of reproductive age seeking a daily, non-invasive method of pregnancy prevention. The high-level action is centered on reliably achieving suppression of ovulation, preventing the monthly release of an egg from the ovary. This dual-hormone structure ensures effective pregnancy prevention by targeting multiple reproductive pathways simultaneously.

Regulatory References

  1. NIH DailyMed label

What side effects are possible with Deso?

Possible Side Effects and Safety Information

The safety profile for Desogestrel/Ethinyl Estradiol (Deso) is formally classified by regulatory authorities (such as the EMA and FDA) based on documented frequency and the affected body system. Adverse reactions are grouped by their estimated occurrence to differentiate between common, expected effects and rare, serious events. This section provides a high-level summary of these official classifications.


Adverse Reactions by Frequency

The most frequently reported effects (Very Common: ge 1 in 10) are typically related to the central and reproductive systems, including Headache and Spotting (intermenstrual bleeding). Common reactions (ge 1 in 100, < 1 in 10) may affect mood (Depressed Mood, Mood Alterations), the gastrointestinal system (Nausea, Abdominal Pain), and include Weight Gain and Breast Tenderness.

Uncommon and Rare classifications cover less frequent effects, such as Fluid Retention or Rash, and include the most serious documented risks.


Serious Safety Considerations

Official labeling consistently highlights the risk of Thromboembolic Events as the principal serious safety concern. These include rare events like Venous Thromboembolism (VTE), which encompasses Deep Vein Thrombosis and Pulmonary Embolism, and Arterial Thromboembolism (ATE), such as Myocardial Infarction and Stroke. The risk of VTE is officially documented as highest during the first year of use.

Use is also associated with an increased risk of developing Hypertension and, rarely, Hepatic Neoplasms (liver tumors). Furthermore, the drug is officially contraindicated in patients with a history of thromboembolic disorders or severe hepatic impairment, or in the presence of undiagnosed abnormal genital bleeding.

Overdose and Emergency Response

Official Overdose Profile and Emergency Action

The regulatory prescribing information for Desogestrel/Ethinyl Estradiol (Deso) describes the manifestations of overdosage as generally not leading to serious or life-threatening acute outcomes. Overdose is officially classified as having a low acute toxicity profile, reflecting that acute ingestion of high amounts of this combined hormonal contraceptive is not typically associated with severe acute systemic toxicity.

Documented Clinical Manifestations The officially documented signs and symptoms following overdosage are confined to expected symptomatic and hormonal effects:

  • Nausea and Vomiting (gastrointestinal manifestations)
  • Withdrawal Bleeding (vaginal bleeding) in female patients

Required Emergency Response As mandated by regulatory authorities, any suspected ingestion exceeding the prescribed dosage requires immediate medical attention. The management of the overdose situation is officially described as symptomatic and supportive treatment, as no specific antidote is documented in the labeling.

When to Seek Help The required emergency action is to seek immediate medical attention or guidance from a Poison Control Center. This step is necessary to initiate appropriate clinical surveillance and supportive care, in accordance with the official overdose instructions for this class of medication.

Therapeutic Uses of Deso

What Deso Treats: Main Uses and Benefits

Based on the therapeutic profile of combination hormonal contraceptives, Desogestrel/Ethinyl Estradiol (Deso) is commonly used for prevention but also provides support that helps ease the overall symptom burden in managing specific conditions involving episodic or fluctuating manifestations related to hormonal cycles.

The medication is generally applied across domains where additional symptomatic support is needed, primarily to support the prevention of pregnancy; for managing cyclical symptoms like painful periods (dysmenorrhea), symptoms of heavy menstrual bleeding (menorrhagia), and cycle irregularity; and for providing supportive therapy for hormonally related acne vulgaris and seborrhea.

“Deso is commonly used when symptoms linked to the menstrual cycle create noticeable physiological strain.”

Quick Fact: Relief for Cyclical Discomfort

The use of Deso in women with certain menstrual disorders may assist with maintaining functional stability by easing symptoms that may become intense or disruptive, relevant in situations where the patient experiences heavy menstrual bleeding and severe cyclical pain.

Regulatory References

  1. NIH StatPearls overview on Oral Contraceptive Pills

Eligibility and Restrictions for Use

The eligibility to use Desogestrel/Ethinyl Estradiol (Deso) is strictly defined by official regulatory documentation and is limited to women of reproductive age seeking pregnancy prevention. Its use is determined by contraindications and specific risk factors.

Eligibility Status Key Regulatory Criteria
Contraindicated (Must Not Use) Use is prohibited for smoking women over 35 years old. It is also forbidden for patients with a history of blood clots (DVT/PE, stroke), uncontrolled severe hypertension, migraine with focal neurological symptoms, active liver disease, or estrogen-dependent cancers (e.g., breast cancer). The medicine is contraindicated if pregnancy is known or suspected.
Restricted or Not Recommended Lactating women are advised against use, as the medicine is transmitted via breast milk. It must be discontinued four weeks prior to and two weeks after major surgery or during prolonged immobilization.
Age Limitations The medicine is not for pre-menarcheal females (before the onset of menstruation) and is not indicated for the elderly, as adequate data is not established for these groups.

The official eligibility profile is defined by a stringent list of absolute contraindications primarily targeting cardiovascular and hepatic risk, dictating precisely who may not use this medicine.

What should I know about interactions with other medicines?

This medication can interact with other drugs and herbal products, which may reduce its effectiveness or increase the risk of certain side effects. Always inform your healthcare provider about all medicines, over-the-counter products, and supplements you are taking.

Interactions that May Decrease Effectiveness

Certain medicines can cause your body to break down the active component of Deso (etonogestrel) faster, lowering its level in the blood. This effect, known as enzyme induction, may increase the risk of an unintended pregnancy or cause breakthrough bleeding. Medicines in this category include:

  • Anticonvulsants: such as phenytoin, phenobarbital, and carbamazepine.
  • Antibiotics/Antimicrobials: specifically rifampicin and rifabutin.
  • Antivirals: certain medications used to treat HIV, such as ritonavir-boosted regimens.
  • Herbal Products: St. John's wort (Hypericum perforatum).

If you take any of these products, your healthcare provider may advise using a different contraceptive method during treatment and for a period after stopping the interacting medication (e.g., for 28 days).

Combinations to Avoid

Combinations with certain antiviral agents, specifically regimens containing Ombitasvir, Paritaprevir, and Ritonavir (with or without Dasabuvir), are generally not recommended or are contraindicated due to the potential for significant liver-related reactions. Additionally, Tranexamic acid should not be taken with this medication.

Mechanism of Action

How Deso Works

Desogestrel’s action is mediated by its active metabolite, Etonogestrel, which operates across two primary mechanistic domains, resulting in specific physiological effects.


Modulating Central Hormonal Pathways

This domain covers the drug’s primary activity: engaging the progestational receptor (PR) within the hypothalamic-pituitary-ovarian (HPO) axis. By activating these receptors, Etonogestrel modifies the early molecular steps that regulate hormone release, suppressing the surge of Luteinizing Hormone (LH) and leading to the suppression of the final hormonal cascade required for ovum release.


Altering Peripheral Signaling and Tissue Dynamics

This mechanism involves the targeted engagement of progesterone receptors in reproductive tissues, specifically the cervix and endometrium. This interaction alters signaling sequences that govern the properties of local secretions and tissue structure, resulting in the peripheral physiological effects of increased cervical mucus viscosity and modification of endometrial structure.

Dosage and Administration Information

How to Use Deso: Official Administration Guidelines

The usage of Desogestrel/Ethinyl Estradiol (Deso) is governed by repeating 28-day cyclic regimens. The primary route of administration for all available forms is oral.


Administration Scope

Instruction Description
Route of Administration Oral. The medication is taken by mouth as a tablet.
Dosing Schedule One tablet daily. The standard regimen involves a 28-day cycle consisting of 21 consecutive days of active (hormonal) tablets followed by a 7-day interval of either inactive (placebo) tablets or a tablet-free period.
Timing Constraint Intake must occur at approximately the same time each day to maintain a consistent hormonal profile.
Intake Condition May be taken with or without food.
Age-Group Rules Postpubertal adolescents are administered the same adult dosing regimens.

Procedural Administration Rules

The official instructions include specific protocols for continuity and adherence:

  • Starting Use: The cycle may be initiated on the first day of the menstrual period (Day 1 Start) or the first Sunday following the period's start (Sunday Start).
  • Contingency for GI Distress: If vomiting or severe diarrhea occurs within 3 to 4 hours of administration, standard protocols require this be treated as a missed dose, necessitating the immediate intake of a replacement tablet.
  • Missed Dose: A specific, cycle-dependent protocol must be followed when an active tablet is missed, varying based on the week of the cycle.
  • Backup Contraception: A barrier method is required during the first 7 days of the first cycle, especially when initiating use under certain conditions.

This structured usage pattern defines the standardized approach to continuous, daily administration and provides the necessary corrective actions for lapses in adherence.

Recent Clinical Evidence

Research Evidence: Overview of Studies for Deso

This section summarizes the formal research used in the regulatory record, outlining the types of studies conducted for the established uses of the medication. The focus is exclusively on the design, populations, and endpoints examined in clinical trials and epidemiological studies.

Evidence for Use in Pregnancy Prevention (Contraception)

The primary role of Deso (Desogestrel/Ethinyl Estradiol) was studied for the prevention of pregnancy. Research involves very large-scale regulatory clinical trials and continuous epidemiological studies that have monitored outcomes across broad populations. The main outcome monitored in these studies is the Pearl Index (PI), a measurement of pregnancy frequency per 100 women-years of exposure. The findings describe patterns observed in the studies where PI measurements were consistently low when the medication was observed in generally healthy women of reproductive age. Comparative evidence against an absolute inactive control (placebo) is not typically standard for this primary purpose.

Evidence for Management of Menstrual Symptoms and Acne

Research has examined Deso in contexts related to symptoms such as primary dysmenorrhea (painful periods). Studies explored outcomes related to physical discomfort by measuring changes in patient-reported outcomes describing perceived discomfort. In women with dysmenorrhea, Randomized Controlled Trials (RCTs) and reviews report how symptoms evolved in the observed populations over defined time intervals. Some trials described patterns such as lower measured pain scores across observed cycles.

For acne vulgaris, comparator-controlled trials examined outcomes linked to inflammatory or irritative states by monitoring changes in total count of acne lesions. Findings describe patterns observed in the studies such as lower measured acne lesion counts over approximately six treatment cycles.

Study Limitations and Research Gaps

Research contains several research limitation frames. Much of the evidence for non-contraceptive uses is often generalized from the Combined Hormonal Contraceptive class rather than being specific to dedicated Deso/EE trials. This means evidence quality varies across studies. Furthermore, there is limited information for long-term outcomes regarding the sustained effects after medication is discontinued. The results apply only to the populations studied, and data for certain groups remain insufficient, such as women at the extremes of body mass index (BMI) ranges.

Key Studies & References

  1. Oral Contraceptive Pills: StatPearls [Internet] – Overview of Mechanism, Indications, and Efficacy
  2. NICE Guideline NG19: Heavy menstrual bleeding: assessment and management
  3. ACOG Practice Bulletin No. 198: Noncontraceptive Uses of Hormonal Contraceptives

Frequently Asked Questions (FAQ)

Common questions about Deso (FAQ)

Q: How is Deso different from similar medicines used for the same thing?

Official documents describe Deso as a Combined Hormonal Contraceptive (CHC). This specific product contains two synthetic hormones: Ethinyl Estradiol (estrogen) and Desogestrel (a third-generation progestin). This combination of active components differentiates it from older or alternative formulations used for pregnancy prevention.

Q: Are there food restrictions to be aware of while using Deso?

Regulatory information indicates that the medication may be taken with or without food. The official administration guidelines do not cite any specific food restrictions that are known to decrease the contraceptive effectiveness of the product.

Q: Does Deso interact with alcohol?

Official regulatory documents do not list alcohol among the drug or herbal products that cause enzyme induction or decrease the contraceptive effectiveness of the medication. The interactions section focuses primarily on other prescription and over-the-counter products that can interfere with the hormones.

Q: Can Deso be split or crushed, according to the official instructions?

The official instructions for Deso define it as an oral tablet intended to be swallowed whole. No instructions for crushing or splitting the tablets are provided in the official administration protocols.

Q: Is Deso known to interact with grapefruit juice?

Official product information does not typically highlight grapefruit juice as a clinically significant interaction that reduces the effectiveness of this contraceptive medication.

Q: Are there different brand names for the medicine Deso?

Yes, the generic drug name is Desogestrel/Ethinyl Estradiol. Official drug databases list this generic medicine under multiple corresponding brand names across different markets where it is available.

Q: How quickly should someone expect Deso to start working?

Contraceptive effectiveness is generally described in official labeling as beginning after the first 7 consecutive days of active tablet intake in the first cycle.

Q: How long does Deso stay in the system?

Pharmacokinetic studies indicate that the active metabolite, Etonogestrel, has an elimination half-life that is generally around 21 to 38 hours at steady state. This half-life supports the medication's requirement for daily dosing to maintain a consistent hormonal profile.

Q: What happens if someone misses taking Deso?

Official labeling includes detailed, cycle-dependent protocols for missed active tablets. The protocol often describes immediately taking the missed dose and may indicate the use of a backup barrier method for a defined period, as procedures are detailed to ensure contraceptive effectiveness is maintained.

Q: Are there any specific vitamins or supplements that are known to interact with Deso?

Regulatory documents primarily list the herbal product St. John's wort (Hypericum perforatum) as a supplement that may cause enzyme induction, potentially reducing the contraceptive effectiveness. Other vitamins are not typically listed as clinically significant interactions.

Q: Is it true that Deso can cause tiredness or fatigue?

Official safety information lists fatigue and weakness as possible side effects. These effects are generally classified as less common than other reported reactions like headache or nausea.

Q: What are the most common side effects people report when taking Deso?

The most frequently reported effects, cited in the Very Common category (ge 1 in 10) in official documents, include Headache and Spotting (intermenstrual bleeding).

Q: Are there any serious side effects associated with Deso that are rare?

Official labeling highlights serious safety concerns, including risks classified as rare (<1 in 1,000). These include Venous Thromboembolism (VTE), Arterial Thromboembolism (ATE), and the potential for Hepatic Neoplasms (liver tumors).

Q: Are there restrictions on who can use Deso based on age?

Official guidelines state that the medicine is not indicated for pre-menarcheal females (before the onset of menstruation) or for the elderly. Additionally, the label restricts use for smoking women over 35 years old due to a significantly increased cardiovascular risk.

Q: Is Deso available as a generic version?

Yes, official regulatory databases indicate that the generic formulation, Desogestrel/Ethinyl Estradiol, is currently available and approved in multiple generic versions by regulatory bodies.

Q: Does taking Deso require any special blood work or monitoring?

Regulatory information advises that periodic follow-up examinations are appropriate for users. This often includes monitoring blood pressure and regularly assessing the presence of any new contraindications.

Q: Is Deso known to affect sleep patterns?

While the official safety information lists effects on the nervous system and mood, disturbances like difficulty sleeping or insomnia are listed as less common or rare side effects in official safety documents.

Q: What should someone do if they accidentally take more Deso than usual?

Official labeling includes protocols for overdose. The information states that serious adverse effects have not been generally reported from taking too many tablets at once, and official information indicates that symptoms may include nausea, vomiting, or withdrawal bleeding.

Q: Can Deso affect a person's mood or emotional state?

Yes, regulatory documents list changes in emotional state. Depressed Mood and Mood Alterations are cited in the Common frequency category (ge 1 in 100 to <1 in 10).

Q: Is it normal for a person to feel no change immediately after starting Deso?

This is normal, as the primary effect is hormonal modulation to suppress ovulation, which is not instantly perceptible. Since the onset of contraceptive protection takes approximately 7 days, no immediate physical changes are typically expected upon taking the first dose.

Q: What does the research say about Deso's effectiveness compared to no treatment?

Regulatory documents state that comparative evidence against an absolute inactive control (placebo) is not standard for this primary purpose (contraception). Effectiveness is measured primarily using the Pearl Index (PI), which tracks pregnancy frequency per 100 women-years of use.

Q: Is Deso ever used in children?

Official administration guidelines state that postpubertal adolescents are administered the same adult dosing regimens. However, it is not indicated for use in pre-menarcheal females (those who have not started menstruating).

Q: Can Deso be taken with over-the-counter cold and flu medicine?

Regulatory warnings focus on specific active ingredients found in certain medicines (e.g., rifampicin, anticonvulsants) that can reduce effectiveness. Most common OTC cold and flu medicines are not listed as having clinically significant interactions that interfere with the contraceptive.

Q: Is there a maximum time frame that Deso is meant to be used?

Official documentation describes the use as a continuous, cyclic, and long-term regimen for generally healthy women seeking contraception. No defined maximum duration for use is established in the product information.

Q: Does Deso cause weight changes?

Official regulatory documents classify Weight Gain as a common side effect (ge 1 in 100 to <1 in 10).

Q: What is the risk of stopping Deso suddenly?

Stopping the medication suddenly will remove its contraceptive effect, and official sources note that fertility can return. The label advises stopping use before major surgery or prolonged immobilization as a safety precaution.

Q: Are there any known interactions between Deso and herbal products?

Yes, official regulatory documents specifically highlight the interaction with the herbal product St. John's wort (Hypericum perforatum). It is noted because it can induce enzymes that break down the drug, potentially reducing contraceptive effectiveness.

Q: Does Deso have any impact on liver function?

Yes, the official label notes that the medication is contraindicated in patients with active liver disease. Furthermore, it is associated with a rare risk of Hepatic Neoplasms (liver tumors).

Q: Is it required to take Deso at the same exact time every day?

Official product information emphasizes that taking the medication at approximately the same time each day helps maintain a consistent hormonal profile for effective contraception.

Q: Are there any specific lifestyle habits that can affect how Deso works?

The most significant lifestyle factor cited in the official contraindications is smoking. For women over 35, smoking is an absolute contraindication due to a significantly increased cardiovascular risk.

Q: What does the official patient information say about Deso and driving?

Official patient information typically states that no or negligible effect on the ability to drive and use machines is expected with the use of the drug.

Q: Is Deso associated with any long-term health risks?

Official labeling highlights the risks of Thromboembolic Events (blood clots) and Hypertension (high blood pressure) as serious long-term safety concerns associated with combined hormonal contraceptives.

Q: Why is Deso sometimes prescribed for uses other than its main indication?

Research has examined the drug for effects related to hormonal symptoms, such as primary dysmenorrhea (painful periods) and acne vulgaris. Studies in these areas focused on monitoring changes in patient-reported discomfort and acne lesion counts.

Q: Is Deso a controlled substance?

No, official regulatory classification systems (such as those in the US and Canada) do not list Desogestrel/Ethinyl Estradiol as a controlled substance.

Q: How does Deso affect people of different genders?

The regulatory labeling defines the target population as women of reproductive age seeking pregnancy prevention. Official product information indicates it is not studied or indicated for use by males.

Q: Are there common reasons a person might be advised to stop using Deso?

Official documents list conditions that necessitate discontinuation, which include the occurrence of a thromboembolic event, uncontrolled hypertension, or the need for major surgery or prolonged immobilization. These factors introduce new or exacerbated risks defined in the official warnings.

Q: How reliable is the evidence supporting Deso's approved uses?

Regulatory documents describe that evidence for non-contraceptive uses is often generalized from the class. Regulatory information indicates that evidence quality varies across studies and that the results apply only to the populations studied in the clinical trials.

How should Deso be stored and disposed of?

How to Store and Dispose of Deso

Desogestrel/Ethinyl Estradiol (Deso) must be stored and disposed of strictly according to regulatory label requirements to ensure stability and public safety.

Storage Conditions

  • Temperature: Store at controlled room temperature, specifically between 20 C and 25 C (68 F and 77 F). Temporary excursions up to 30 C (86 F) are permitted.
  • Protection: The medicine must be protected from both light and moisture.
  • Packaging: Keep the tablets in the original container (blister pack) and protective pouch to maintain integrity and stability.
  • Safety: The product must be stored out of the sight and reach of children.

Disposal Instructions

  • Dispose of any unused or expired product in accordance with local requirements.
  • Do not flush the tablets down the toilet or throw them in the household trash unless specifically instructed by an official medicine take-back program.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Deso found in:

A-Z Index: